Abstract-Focused ultrasound (FUS) in the presence of systemically administered microbubbles has been shown to locally, transiently and reversibly increase the permeability of the blood-brain barrier (BBB), thus allowing targeted delivery of therapeutic agents in the brain for the treatment of central nervous system diseases. Currently, microbubbles are the only agents that have been used to facilitate the FUS-induced BBB opening.
INTRODUCTION
Focused ultrasound (FUS)-induced blood-brain barrier (BBB) opening has been shown to hold great promise for targeted drug delivery in the brain for the treatment of central nervous system diseases [1, 2] . Various therapeutic agents have been delivered across the BBB and shown capable of inducing therapeutic effects using this technology [2, 3] . The FUS-microbubble-based drug delivery system relies on the capability of systemically-administered and acoustically-activated microbubbles to noninvasively, transiently and reversibly increase the cellular and vascular permeability of the BBB, thus allowing drug molecules that are normally restricted within the vasculature to cross the barrier and be delivered to the brain parenchyma.
Currently, FUS-induced BBB opening has only been achieved using commercially available [1] or in-house manufactured gaseous microbubbles [4] . Despite their utility as mediating vehicles, microbubbles can only be used as vascular contrast agents since their size (typically 1-10 μm) prevents their extravasation, limiting the cavitation effects to regions at or near the vessels. Using fluorescence microscopy, our group [5] previously showed that homogeneous distribution of relatively larger dextran molecules (10 kDa and 70 kDa) was more difficult to achieve than with smaller ones (3 kDa), highlighting the need for an agent with greater ability to induce molecular diffusion beyond the cerebral vasculature.
Phase-shift perfluorocarbon droplets may potentially offer the solution for such a demand [6] . Initially in the liquid state, nanoscale droplets show high stability in circulation and can be generated in sizes small enough to extravasate through leaky vasculature; but once exposed to sufficient rarefactional pressures, they expand to form microbubbles capable of oscillation in a similar fashion as traditional microbubbles. For the purposes of BBB opening, these agents may present a unique opportunity. Because droplet activation is dependent on the local rarefactional pressure, the microbubbles will only be generated within the narrow focal region where acoustic properties are the strongest, ensuring the therapeutic effect is limited to the desired treatment areas [7] .
Once initial BBB permeabilization is achieved, the droplets remaining will be small enough for potential extravasation during subsequent passes through the vasculature. Once entered into the interstitial space behind the barrier, the droplets could then be acoustically activated to form vaporized gaseous bubbles outside the constraints of the cerebral microvessels. Therefore, the possibility exists for an extravascularly activated contrast agent for enhanced drug delivery at sites that are located deeply in the brain tissue or at regions with relatively low vasculature density.
The main objective of the present study was to show the feasibility of utilizing phase-shift nanodroplets as the mediating agents for targeted drug delivery using FUSinduced BBB opening. Conventional in-house generated microbubbles with the same lipid shell composition and perfluorocarbon core were also used as the "standard" for comparing the efficiency of BBB opening based on targeted delivery of fluorescent dextran. A series of clinically relevant acoustic exposures were used to further demonstrate the safety of this technology for drug delivery in the brain.
II. METHODS

A. Contrast Agent Generation
Microbubbles (1,2-disterayol-sn-glycero-3-phosphocholine (DSPC) and 1,2-disterayol-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethlyne glycol)2000] (DSPE-PEG2000) at a molar ratio of 90:10) were generated via mechanical agitation. A Multisizer III particle counter (Beckman Coulter, Opa Locka, FL) was used to measure the microbubble size distribution and concentration. Nanodroplets were generated via microbubble condensation, in which pre-formed microbubbles were reverted to the liquid state by application of reduced temperature and increased ambient pressure [6] . A Malvern Nano Zetasizer (Malvern Instruments, Ltd., Marlvern, Worcestershire, U.K.) was used to measure the nanodroplet size distribution.
B. In vivo FUS-Induced BBB Opening
All experiments were performed in accordance with procedures approved by the Columbia University Institutional Animal Care and Use Committee. A total of 80 male C57BL/6 mice (Harlan Laboratories; Indianapolis, IN) were divided into two experimental groups using either nanodroplets (group #1) or microbubbles (group #2) as the mediating agents for FUS-induce BBB opening. The experimental setup was used as previously described [7] . Pulsed FUS (pulse length: 67 ms; pulse repetition frequency: 5 Hz; duration: 5 min) at acoustic pressures ranging between 0.15 and 0.60 MPa was applied transcranially to the targeted left hippocampus of the mouse brain while the right hippocampus served as the control. The injected contrast agents were freshly diluted (nanodroplets: 50 vol% dilution; microbubbles: final concentration 8x10 8 #/mL) and coinjected with 3 kDa fluorescent dextran via mouse tail vein. The animal was sacrificed 1 h after sonication, and the mouse brain was processed for either fluorescence imaging or histological staining.
C. Data Analysis
The extent of BBB opening was determined based on the quantification of dextran delivery into the targeted hippocampus. The fluorescence enhancement was calculated following our previously published protocol [3] . The acoustic emission, as quantified by stable cavitation dose (SCD) and inertial cavitation dose (ICD), was also calculated to that described previously [7] . All statistical analyses were done using unpaired two-tailed Student's t-test in GraphPad Prism (La Jolla, CA).
III. RESULTS
A. Contrast Agent Generation
The PFB phase-shift nanodroplet emulsions appeared partially translucent and were similar in stability and size to previously reported results [6] . The averaged numberweighted mean and median diameters across all samples were 204±10 nm and 209±29 nm, respectively. The mechanical agitation method produced opaque milky microbubble suspensions that were stable during the experimental timeframe. The averaged number-weighted mean and median diameters were 1.36±0.32 μm and 0.86±0.35 μm, respectively.
B. In vivo FUS-Induced BBB Opening
The extent of the FUS-induced BBB opening could be quantified as the relative fluorescence enhancement in the sonicated hippocampus over the control.
Following nanodroplets-mediated BBB opening, a significant increase in dextran delivery in the targeted region was observed at 0.45 and 0.60 MPa (60% opening efficiency and 100% opening efficiency, respectively) while only up to 33% of the animals evaluated showed a significant fluorescence enhancement when sonicated at pressures below 0.45 MPa. Due to the inconsistency across animals, there was no statistically significant increase in fluorescence enhancement to clearly indicate BBB opening for sonication pressures between 0.15 and 0.30 MPa (Fig. 1A) . At pressures above 0.45 MPa, fluorescence was observed not only within or near large vessels, but also diffusely distributed across the hippocampi (Figs. 2D and 2E) .
Following the systemic administration of microbubbles and subsequent BBB opening, a significant fluorescence enhancement was detected for all mice when sonicated at pressures including and above 0.30 MPa. A similar inconsistency of dextran delivery across animals was seen at 0.225 MPa that only 3 out of 5 mice showed significant fluorescence enhancement in the targeted region. Thus, no sufficient statistical difference could be obtained to unequivocally show BBB opening at pressures below 0.30 MPa (Fig. 1B) . The detectable fluorescence signal was predominately contained within vessels at 0.30 MPa but more diffusely distributed throughout the targeted region at 0.45 MPa, indicating a more homogenous distribution of dextran molecules (Figs. 2H and 2I ). At 0.60 MPa, heterogeneous spots of particularly high levels of fluorescence in combination with diffusely distributed fluorescence was observed (Fig. 2J) . Fig. 1 . Normalized fluorescence enhancement between the targeted and the control hippocampi using either nanodroplets (A) or microbubbles (B) to mediate BBB opening at distinct sonication pressures. Significant dextran delivery was observed at pressures higher than 0.45 MPa using nanodroplets while the BBB opening threshold was decreased down to 0.30 MPa when microbubbles were administered. (ns: not significant; *: P<0.05; **: P<0.01; ***: P<0.001) Fig. 3 shows the quantitative acoustic emission results detected before and after the contrast agent administrations at various sonication pressures. For nanodroplets, the quantified SCD showed significant increase at 0.60 MPa (Fig. 3A) , corresponding to the significant dextran delivery detected based on fluorescence microscopy. However, no statistical difference was determined at 0.45 MPa despite a 90% mean signal increase after nanodroplet injection owing to the large variations among different mice. The quantified ICD, on the other hand, showed no detectable increase across all pressures (Fig. 3B) , implying that no significant vaporized droplet fragmentation was detected.
C. Contrast Agent-Dependent BBB Opening Threshold
Interestingly, the SCD for group #2 showed significant increase for all pressures regardless the outcome of the BBB opening (Fig. 3C) .
The ICD measurement showed significant signal increase after microbubble injection at 0.60 MPa but not at other pressures, indicating microbubbles underwent inertial fragmentation during sonication only at the highest acoustic exposure (Fig. 3D) .
A cavitation dose opening threshold can also be derived when SCD was grouped based on the BBB opening results (Fig. 4) . For group #1, a statistically higher stable cavitation emission was detected for cases where significant fluorescence enhancement was measured. The highest SCD value, at which no evidence of dextran delivery was detected, was 74 V·s. Out of the 10 animals that showed significant fluorescence increase, 3 mice (30%) had their SCD lower than 74 V·s, suggesting that this level could be used as the threshold for predicting successful BBB opening using nanodroplets as the contrast agents. Interestingly, the acoustic threshold of BBB opening appeared to be contrast agent-dependent. For group #2, the highest SCD value, for which no detectable dextran delivery was observed, was 1.4 kV·s, significantly higher than the SCD threshold found for group #1. A much more prominent threshold was found for group #2 since 1 out of 15 mice (6.7%) with significant fluorescence enhancement had a SCD lower than 1.4 kV·s. The threshold for predicting FUS-induced BBB opening in the presence of microbubbles was therefore concluded to be 1.4 kV·s (Fig. 4) .
IV. DISCUSSION
The current study utilized acoustically-activated droplets as a new class of contrast agents to facilitate targeted drug delivery in the brain after FUS-induced BBB opening in mice. Using fluorescent dextran, the extent of the BBB opening was quantified and compared between nanodroplets and the conventional microbubbles. The acoustic emission generated from the contrast agents during sonication was captured in order to gain insights to their cavitation characteristics. Interestingly, the acoustic threshold, at which significant dextran delivery was observed, appeared to be contrast agent dependent. Our results suggested that future contrast agent-specific monitoring during FUSinduced BBB opening might be needed.
Previous work reported by our group and others have been focusing on increasing the delivered dose and distribution by optimizing ultrasonic parameters [5, 8] and microbubble characteristics [9] . Choi et al. [5] showed that homogenous distribution of 3 kDa dextran molecules was possible by incorporating short ultrasonic pulses to allow sufficient microbubble replenishment at the focus during The utilization of acoustically vaporized nanodroplets in this paper produced a similar homogenous dextran distribution throughout the targeted volume (Figs.  2D-2J ). Similar to our previous studies, fluorescence was not only detected within or near large vessels but also diffusely distributed within the hippocampus, thus showing greater promise for delivery of therapeutic agents to a wider range of cellular targets outside the microvasculature. As a preliminary study, the sonication parameters used in the current study were simply adapted based on our previous experiments using microbubbles. Therefore, it is possible that droplet-specific pulse sequence could be custom designed to further enhance the delivery of larger drug molecules. In addition, it is possible that a higher but safer sonication pressure could be achieved with nanodroplets since the threshold for inducing inertial cavitation was higher than that of microbubbles (Figs. 3B and 3D) .
Passively detected acoustic emissions originated from the oscillating contrast agents were used to characterize the type of cavitation events occurred during sonication, providing insights to the mechanism of the FUS-induced BBB opening.
Only an increase in the harmonics and ultraharmonics signals detected after nanodroplet injection at all pressures, suggesting that the vaporized nanodroplet underwent mainly stable cavitation during sonication. Interestingly, when microbubbles were used as the mediating agent, significant SCD increase was seen across all pressures regardless of the outcome of BBB opening (Fig. 3C) . This result was further demonstrated in Fig. 4 , in which significant difference was calculated between threshold baselines.
This finding was deemed very important for acoustic emission based BBB opening monitoring since contrast agent-specific thresholds would then need to be investigated separately.
V. CONCLUSION
In this paper, we have performed a feasibility study to explore the utilization of phase-shift nanodroplets for targeted drug delivery in the brain with FUS-induced BBB opening. Significant dextran delivery was achieved in the mouse hippocampus using acoustically-activated nanodroplets at clinically relevant pressures. Conventional microbubbles with the same lipid shell composition and perfluorobutane core as the nanodroplets were also used to compare the efficiency of FUS-induced dextran delivery. It was found that nanodroplets had a higher BBB opening pressure threshold but a lower stable cavitation threshold than the microbubbles.
More homogeneous dextran delivery within the targeted hippocampus was achieved using nanodroplets without inducing inertial cavitation or compromising safety. Our results offered a new means of developing the FUS-induced BBB opening technology for potential extravascular targeted drug delivery in the brain. Fig. 4 . Stable cavitation dose-indicated BBB opening threshold. The SCD was grouped based on whether significant dextran delivery was detected. Sonication using microbubbles as the contrast agents produced a much wider range of SCD comparing to when nanodroplets were used. The SCD threshold for predicting BBB opening appeared to be contrast agent dependent. 7 out of 10 mice showed significant dextran delivery with SCD greater than 74 V·s using nanodroplets while 92.3% of the animals showed significant dextran delivery at SCD above 1.4 kV·s using microbubbles. (*: P<0.05; ***: P<0.001)
